Abstract:Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibody-drug conjugates (ADCs) are a class of therapeutics that combines an antigen-specific antibody backbone with a potent cytotoxic payload, resulting in an improved therapeutic index. Two anti-HER2 ADCs have been approved by the FDA with different indications in HER2-positive breast cancer. Ado-trastuzumab emtansine (T-DM1) was the first-in-class HER2-targeting ADC, initially approved in 2013 for metastatic patients who previously received trastuzumab and a taxane, and the label was expanded in 2019 to include adjuvant treatment of high-risk patients with residual disease after neoadjuvant taxane and trastuzumab-based therapy. In 2020, trastuzumab deruxtecan (T-DXd) was the second approved ADC for patients who had received at least 2 lines of anti-HER2-based therapy in the metastatic setting. The success of these two agents has transformed the treatment of HER2-positive breast cancer and has re-energized the field of ADC development. Given their advanced pharmaceutical properties, next-generation HER2-targeted ADCs have the potential to be active beyond traditional HER2-positive breast cancer and may be effective in cells with low expression of HER2 or ERBB2 mutations, opening a spectrum of new possible clinical applications. Ongoing challenges include improving target-specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection. The aim of this review is to summarize the principal molecular, clinical, and safety characteristics of approved and experimental anti-HER2 ADCs, contextualizing the current and future landscape of drug development.

Targeting HER2-positive breast cancer: advances and future directions

Emerging Targeted Therapies for HER2-Positive Breast Cancer

Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment

HER2-targeted therapies beyond breast cancer - an update

Updates in Treatment of HER2-positive Metastatic Breast Cancer

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

HER2-targeted therapies in cancer: a systematic review

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

The Exciting New Field of HER2-Low Breast Cancer Treatment

Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer

Recent advances in nanoscale targeted therapy of HER2-positive breast cancer

Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)

HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers

Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer

Monoclonal Antibody-Based Targeted Therapy in Breast Cancer

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

HER2-low breast cancers: Current insights and future directions